Taking kratom while breastfeeding is not considered safe. No studies have measured how much kratom passes into breast milk, which means there is no established safe dose, and the risks to an infant are largely unknown. What is known, from case reports and pharmacology, points toward real potential for harm.
Why the Risk Is Hard to Measure
The main active compound in kratom, mitragynine, acts on the same brain receptors as opioids. It has a half-life of roughly 3 to 9 hours, meaning it lingers in the body for an extended period before being fully cleared. Many opioid-type substances do transfer into breast milk, and compounds with similar properties to mitragynine are generally expected to as well.
The U.S. National Library of Medicine’s Drugs and Lactation Database (LactMed), which tracks what is known about medications and breast milk, lists kratom but states plainly: no published data exists on maternal milk levels, infant blood levels, or effects on milk production. This isn’t reassuring. It means no researcher has been able to confirm a safe threshold, and no one has systematically tracked what happens to breastfed infants whose mothers use kratom regularly.
What Has Been Seen in Newborns
While most documented cases involve prenatal exposure rather than exposure purely through breast milk, they reveal how sensitive infants are to kratom’s opioid-like effects. In one published case, a newborn developed withdrawal symptoms within 24 hours of birth. The signs included jitteriness, excessive crying, increased muscle tone, sneezing, rapid breathing, and elevated body temperature. The infant also had an excessive sucking reflex paired with poor feeding and spitting up. Clinicians described these symptoms as consistent with opioid withdrawal.
A systematic review of outcomes in kratom-exposed mothers and newborns identified multiple cases where infants were breastfed and at least one was diagnosed with neonatal abstinence syndrome on day four after birth. These cases make it difficult to separate what came from prenatal exposure versus breast milk exposure, but they confirm that kratom’s active compounds reach infants and produce measurable opioid-like effects in their developing nervous systems.
How Kratom Differs From Monitored Medications
Some opioid-based medications, like those used in addiction treatment, are sometimes considered compatible with breastfeeding under medical supervision. The key difference is that those medications have been extensively studied. Doctors know exactly how much transfers into milk, what concentration is safe for the infant, and how to monitor for problems.
Kratom has none of that infrastructure. It is sold as an unregulated supplement, so the actual concentration of active compounds varies widely between products. One batch could contain significantly more mitragynine than another. This inconsistency makes it impossible to estimate how much an infant would actually receive through breast milk on any given day, even if a mother uses the same product regularly.
Contamination Adds Another Layer of Risk
Because kratom is not regulated as a pharmaceutical, products are not held to the same purity standards as prescription drugs. The FDA has flagged concerns about contamination in kratom products, including the potential for heavy metals and bacterial contamination. An infant’s developing organs, particularly the liver and kidneys, are far less equipped to handle these contaminants than an adult’s.
The FDA’s Position
The FDA has warned consumers broadly against using kratom, citing risks of liver toxicity, seizures, and substance use disorder. The agency has also specifically acknowledged cases of neonatal abstinence syndrome in newborns with prolonged kratom exposure before birth, noting withdrawal signs like jitteriness, irritability, and muscle stiffness. As of December 2025, the FDA continues to take enforcement action against companies making health claims about kratom products.
If You Currently Use Kratom
If you are breastfeeding and using kratom for pain management, energy, or to manage withdrawal from other substances, the safest step is to work with a healthcare provider who can help you find an alternative with a known safety profile during lactation. Abruptly stopping kratom can cause its own withdrawal symptoms, so a guided approach is more practical than quitting cold turkey.
For those using kratom to manage opioid dependence specifically, supervised treatment options exist that have been studied in breastfeeding mothers and have established safety data. Switching to a monitored option allows you to continue breastfeeding while reducing the unknowns your infant is exposed to. The core issue with kratom during breastfeeding is not that harm has been proven beyond doubt. It is that safety has never been demonstrated, the product itself is unpredictable, and the available case evidence consistently points in a concerning direction.